|
Status |
Public on Aug 26, 2020 |
Title |
LP-1 WT-DMSO_rep1 |
Sample type |
SRA |
|
|
Source name |
LP-1WT_DMSO1
|
Organism |
Homo sapiens |
Characteristics |
cell type: B lymphoblast tumor type: mutiple myeloma cell line: LP-1 phenotype: WT treatment: untreated
|
Treatment protocol |
Cell was 25nM SI-2 treated for 24 hours.
|
Growth protocol |
LP-1 wild-type cell and bortezomib-resistant cell were cultured in RPMI-1640 medium with 10% FBS.
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was harvested using Trizol reagent. RNA libraries were prepared for sequencing using BGI protocols
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
BGISEQ-500 |
|
|
Data processing |
Basecalls performed using BGISEQ-500 SOAPnuke was used to get the "clean reads". Mapping clean reads to hg19 whole genome using BWA. Bowtie2 was used to get the mapping ratio. Fragments Per Kilobase Million (FPKM) was calculated based on the RSEM. Genome_build: hg19 Supplementary_files_format_and_content: tab-delimited text files include fpkm values for each Sample
|
|
|
Submission date |
Aug 25, 2020 |
Last update date |
Aug 26, 2020 |
Contact name |
Liu Zhiqiang |
E-mail(s) |
zhiqiangliu@tmu.edu.cn
|
Organization name |
Tianjin Medical University
|
Street address |
22 Qxiangtai Rd
|
City |
Tianjin |
ZIP/Postal code |
300070 |
Country |
China |
|
|
Platform ID |
GPL23227 |
Series (2) |
GSE156871 |
Targeting steroid receptor co-activator 3 sensitizes myeloma cell to proteasome inhibitor treatment through NSD2-mediated phase separation and chromatin remodeling [RNA-Seq] |
GSE156872 |
Targeting steroid receptor co-activator 3 sensitizes myeloma cell to proteasome inhibitor treatment through NSD2-mediated phase separation and chromatin remodeling |
|
Relations |
SRA |
SRX9006286 |
BioSample |
SAMN15904266 |